Tag - AUTL

Developments

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

Autolus Therapeutics (NASDAQ: AUTL) has announced that the European Commission (EC) has granted marketing authorization for AUCATZYL for the treatment of adult patients aged 26 and over with relapsed or refractory B...

July 21, 2025

Markets

HCW cuts Autolus PT to $24 from $41

H.C. Wainwright lowered its price target for Autolus Therapeutics plc (NASDAQ:AUTL) to $24 from $41 after significant changes to its pipeline and timelines were disclosed in the company’s second quarter results. The...

August 12, 2019

Developments

Autolus Therapeutics ALL treatment gets FDA orphan drug designation

Autolus Therapeutics’ (NASDAQ:AUTL) AUTO3 has received FDA orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL). AUTO3 is a T-cell therapy produced by genetically modifying a patient’s own T...

April 23, 2019

Tag - AUTL

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

HCW cuts Autolus PT to $24 from $41

Autolus Therapeutics ALL treatment gets FDA orphan drug designation

Subscribe